Related references
Note: Only part of the references are listed.Effects of bisphosphonates on osteoporosis: Focus on zoledronate
Ahmad Oryan et al.
LIFE SCIENCES (2021)
Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives
Chenggui Zhang et al.
FRONTIERS IN PHARMACOLOGY (2021)
Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?
Felicia Cosman et al.
CURRENT OSTEOPOROSIS REPORTS (2021)
Raloxifene has favorable effects on the lipid profile in women explaining its beneficial effect on cardiovascular risk: A meta-analysis of randomized controlled trials
Fang Yang et al.
PHARMACOLOGICAL RESEARCH (2021)
New Frontiers in Osteoporosis Therapy
Cheng Cheng et al.
ANNUAL REVIEW OF MEDICINE, VOL 71, 2020 (2020)
Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Second rebound-associated vertebral fractures after denosumab discontinuation
Rui Niimi et al.
ARCHIVES OF OSTEOPOROSIS (2020)
A Review on the Role of Denosumab in Fracture Prevention
Kok-Lun Pang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment reinitiation
Athanasios D. Anastasilakis et al.
BONE REPORTS (2020)
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline
Richard Eastell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis
Patricia Barrionuevo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Clinical Update on Osteoporosis
Angelina Anthamatten et al.
JOURNAL OF MIDWIFERY & WOMENS HEALTH (2019)
Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials
Adrian Hernandez et al.
MATURITAS (2019)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials
Y. Liu et al.
CLIMACTERIC (2018)
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
David L. Kendler et al.
LANCET (2018)
Correlates of Selected Biochemical Markers of Bone turnover among Post-Menopausal Women
Bikram Khadka et al.
JOURNAL OF NEPAL MEDICAL ASSOCIATION (2018)
Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis
T. Saito et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2017)
International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates
A. Diez-Perez et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2017)
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Robert A. Adler et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Bazedoxifene and Conjugated Equine Estrogen: A Combination Product for the Management of Vasomotor Symptoms and Osteoporosis Prevention Associated with Menopause
Elena M. Umland et al.
PHARMACOTHERAPY (2016)
Antiresorptives and anabolic therapy in sequence or combination for postmenopausal osteoporosis
S. Palacios et al.
CLIMACTERIC (2015)
The Effect of 6 Versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Burden of Illness for Osteoporotic Fractures Compared With Other Serious Diseases Among Postmenopausal Women in the United States
Andrea Singer et al.
MAYO CLINIC PROCEEDINGS (2015)
A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture
Santiago Palacios et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2015)
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
S. Papapoulos et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women
Alexandra G. Ellis et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Effects of Bazedoxifene/Conjugated Estrogens on the Endometrium and Bone: A Randomized Trial
Joann V. Pinkerton et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Osteoporosis and Its Complications
Matthew A. Varacallo et al.
MEDICAL CLINICS OF NORTH AMERICA (2014)
Bazedoxifene versus Oral Bisphosphonates for the Prevention of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis at Higher Risk of Fracture: A Network Meta-Analysis
Alexandra G. Ellis et al.
VALUE IN HEALTH (2014)
Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis
Lydia Gedmintas et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
M. R. McClung et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Eliminating the need for fasting with oral administration of bisphosphonates
Michael Pazianas et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2013)
Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension
Socrates Papapoulos et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study
S. L. Silverman et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
N. Freemantle et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk
S. Boonen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial
T. J. de Villiers et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Femoral Bone Strength and Its Relation to Cortical and Trabecular Changes After Treatment With PTH, Alendronate, and Their Combination as Assessed by Finite Element Analysis of Quantitative CT Scans
Tony M. Keaveny et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Estrogen agonists/antagonists in combination with estrogen for prevention and treatment of menopause-associated signs and symptoms
Dale W. Stovall et al.
WOMENS HEALTH (2008)
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women
Elizabeth Barrett-Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study
PD Delmas et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial
PD Delmas et al.
BONE (2003)
Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
IR Reid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
